Sophiris Bio Company Profile (NASDAQ:SPHS)

About Sophiris Bio (NASDAQ:SPHS)

Sophiris Bio logoSophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SPHS
  • CUSIP: N/A
  • Web: www.sophiris.com
Capitalization:
  • Market Cap: $70.29 million
  • Outstanding Shares: 30,111,000
Average Prices:
  • 50 Day Moving Avg: $2.03
  • 200 Day Moving Avg: $2.32
  • 52 Week Range: $1.80 - $3.48
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.09
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.44 per share
  • Price / Book: 5.32
Profitability:
  • EBIDTA: ($11,200,000.00)
  • Return on Equity: -83.08%
  • Return on Assets: -39.68%
Debt:
  • Current Ratio: 15.08%
  • Quick Ratio: 15.08%
Misc:
  • Average Volume: 187,975 shs.
  • Beta: 1.52
  • Short Ratio: 17.83
 

Frequently Asked Questions for Sophiris Bio (NASDAQ:SPHS)

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

How were Sophiris Bio's earnings last quarter?

Sophiris Bio, Inc. (NASDAQ:SPHS) posted its earnings results on Monday, May, 15th. The company reported ($0.09) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.00. View Sophiris Bio's Earnings History.

When will Sophiris Bio make its next earnings announcement?

Sophiris Bio is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Sophiris Bio.

Where is Sophiris Bio's stock going? Where will Sophiris Bio's stock price be in 2017?

5 equities research analysts have issued twelve-month price objectives for Sophiris Bio's shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Sophiris Bio's stock price to reach $6.60 in the next twelve months. View Analyst Ratings for Sophiris Bio.

Who are some of Sophiris Bio's key competitors?

Who owns Sophiris Bio stock?

Sophiris Bio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.43%), Palo Alto Investors LLC (0.82%), Mesirow Financial Investment Management Inc. (0.18%) and JPMorgan Chase & Co. (0.08%). View Institutional Ownership Trends for Sophiris Bio.

Who sold Sophiris Bio stock? Who is selling Sophiris Bio stock?

Sophiris Bio's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. View Insider Buying and Selling for Sophiris Bio.

Who bought Sophiris Bio stock? Who is buying Sophiris Bio stock?

Sophiris Bio's stock was acquired by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Sophiris Bio.

How do I buy Sophiris Bio stock?

Shares of Sophiris Bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sophiris Bio's stock price today?

One share of Sophiris Bio stock can currently be purchased for approximately $2.34.


MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sophiris Bio (NASDAQ:SPHS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.60 (182.05% upside)

Analysts' Ratings History for Sophiris Bio (NASDAQ:SPHS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017HC WainwrightReiterated RatingBuy$6.00LowView Rating Details
8/14/2017Maxim GroupSet Price TargetBuy$6.00LowView Rating Details
6/1/2017Rodman & RenshawReiterated RatingBuy$6.00HighView Rating Details
4/6/2017Piper Jaffray CompaniesReiterated RatingOverweight$7.00MediumView Rating Details
11/11/2016Roth CapitalReiterated RatingBuy$8.00N/AView Rating Details
6/10/2016Echelon Wealth PartnersReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Sophiris Bio (NASDAQ:SPHS)
Earnings by Quarter for Sophiris Bio (NASDAQ:SPHS)
Earnings History by Quarter for Sophiris Bio (NASDAQ SPHS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.10)N/AView Earnings Details
5/15/2017Q1 2017($0.09)($0.09)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.11)($0.02)ViewN/AView Earnings Details
5/16/2016Q1($0.19)($0.13)ViewN/AView Earnings Details
3/23/2016Q4($0.15)ViewN/AView Earnings Details
11/16/2015Q3($0.22)ViewN/AView Earnings Details
5/13/2015($0.30)($0.26)ViewN/AView Earnings Details
3/10/2015($0.47)($0.31)ViewN/AView Earnings Details
11/13/2014($0.54)($0.49)ViewN/AView Earnings Details
5/13/2014Q114($0.50)($0.52)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sophiris Bio (NASDAQ:SPHS)
2017 EPS Consensus Estimate: ($0.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.08)($0.08)($0.08)
Q2 20171($0.08)($0.08)($0.08)
Q3 20171($0.09)($0.09)($0.09)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sophiris Bio (NASDAQ:SPHS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sophiris Bio (NASDAQ:SPHS)
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 6.01%
Insider Trades by Quarter for Sophiris Bio (NASDAQ:SPHS)
Institutional Ownership by Quarter for Sophiris Bio (NASDAQ:SPHS)
Insider Trades by Quarter for Sophiris Bio (NASDAQ:SPHS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2014Boxer Capital, LlcMajor ShareholderSell881,479$0.61$537,702.19View SEC Filing  
11/14/2014Randall E WoodsInsiderBuy3,000$2.43$7,290.00View SEC Filing  
9/19/2014Gerald T ProehlDirectorBuy10,000$3.16$31,600.00View SEC Filing  
7/10/2014Randall E WoodsInsiderBuy1,000$2.65$2,650.00View SEC Filing  
7/9/2014Randall E WoodsInsiderBuy1,000$2.66$2,660.00View SEC Filing  
6/6/2014James L HeppellDirectorSell19,231$2.59$49,808.29View SEC Filing  
8/22/2013Randall E WoodsCEOBuy2,500$4.50$11,250.00View SEC Filing  
8/20/2013Peter T SloverCFOBuy4,680$4.25$19,890.00View SEC Filing  
8/19/2013Randall E WoodsCEOBuy10,000$4.29$42,900.00View SEC Filing  
8/16/2013Boxer Capital, LlcMajor ShareholderBuy1,600,000$5.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sophiris Bio (NASDAQ:SPHS)
Latest Headlines for Sophiris Bio (NASDAQ:SPHS)
Source:
DateHeadline
americanbankingnews.com logoHC Wainwright Reaffirms "Buy" Rating for Sophiris Bio, Inc. (SPHS)
www.americanbankingnews.com - September 15 at 4:52 PM
finance.yahoo.com logoSophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank
finance.yahoo.com - September 14 at 10:28 AM
americanbankingnews.com logoSophiris Bio, Inc. (SPHS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 9 at 2:50 PM
prnewswire.com logoSophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - PR Newswire (press release)
www.prnewswire.com - August 19 at 7:44 AM
finance.yahoo.com logoSophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - August 18 at 7:27 AM
americanbankingnews.com logoQ3 2017 Earnings Forecast for Sophiris Bio, Inc. Issued By Zacks Investment Research (SPHS)
www.americanbankingnews.com - August 18 at 6:24 AM
americanbankingnews.com logoSophiris Bio, Inc. (SPHS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 6:32 PM
americanbankingnews.com logoHC Wainwright Reiterates "$6.00" Price Target for Sophiris Bio, Inc. (SPHS)
www.americanbankingnews.com - August 13 at 3:32 PM
finance.yahoo.com logoSophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights
finance.yahoo.com - August 11 at 8:45 AM
americanbankingnews.com logo Brokerages Anticipate Sophiris Bio, Inc. (SPHS) to Post -$0.09 Earnings Per Share
www.americanbankingnews.com - July 25 at 9:03 AM
americanbankingnews.com logoContrasting Parnell Pharmaceuticals Holdings (PARN) and Sophiris Bio (SPHS)
www.americanbankingnews.com - July 23 at 7:25 AM
americanbankingnews.com logoSophiris Bio, Inc. (NASDAQ:SPHS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 21 at 6:50 PM
americanbankingnews.com logoMylan N.V. (MYL) and Sophiris Bio (SPHS) Head-To-Head Review
www.americanbankingnews.com - July 16 at 6:20 PM
americanbankingnews.com logoComparing Sophiris Bio (SPHS) & Mylan N.V. (MYL)
www.americanbankingnews.com - July 11 at 8:26 PM
americanbankingnews.com logoFinancial Analysis: Parnell Pharmaceuticals Holdings (PARN) & Sophiris Bio (NASDAQ:SPHS)
www.americanbankingnews.com - July 8 at 2:18 PM
americanbankingnews.com logoSophiris Bio (SPHS) vs. Parnell Pharmaceuticals Holdings (PARN) Head to Head Analysis
www.americanbankingnews.com - June 29 at 4:07 PM
americanbankingnews.com logo Analysts Expect Sophiris Bio, Inc. (SPHS) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - June 29 at 12:16 AM
americanbankingnews.com logoSophiris Bio, Inc. (SPHS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 8:56 PM
finance.yahoo.com logoSophiris Bio Added to Russell Microcap Index
finance.yahoo.com - June 24 at 6:55 AM
americanbankingnews.com logoSophiris Bio, Inc. (SPHS) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - June 13 at 3:28 PM
americanbankingnews.com logoSophiris Bio, Inc. (SPHS) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - June 11 at 10:52 PM
americanbankingnews.com logoMaxim Group Analysts Give Sophiris Bio Inc (SPHS) a $6.00 Price Target
www.americanbankingnews.com - June 11 at 8:30 AM
streetinsider.com logoSophiris Bio (SPHS) Doses First Patient in Phase 2b Study of Topsalysin to Treat Prostate Cancer - StreetInsider.com
www.streetinsider.com - June 10 at 1:13 AM
nasdaq.com logoSophiris Bio Begins Dosing Patients in Phase 2b Study of Topsalysin to Treat Prostate Cancer
www.nasdaq.com - June 9 at 12:06 AM
finance.yahoo.com logoSophiris Bio Announces that the First Patient Has Been Dosed in Phase 2b Study of Topsalysin in Patients with Clinically Significant Localized Prostate Cancer
finance.yahoo.com - June 8 at 8:06 AM
americanbankingnews.com logo Analysts Expect Sophiris Bio Inc (SPHS) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - June 2 at 10:26 PM
americanbankingnews.com logoSophiris Bio Inc (SPHS) Receives Buy Rating from Rodman & Renshaw
www.americanbankingnews.com - June 1 at 7:28 PM
americanbankingnews.com logoSophiris Bio Inc (SPHS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 6:34 PM
finance.yahoo.com logoSophiris Bio Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer
finance.yahoo.com - May 23 at 7:20 PM
americanbankingnews.com logoFY2017 EPS Estimates for Sophiris Bio Inc Decreased by Zacks Investment Research (SPHS)
www.americanbankingnews.com - May 22 at 7:18 AM
finance.yahoo.com logoSPHS: Dosing of Patients in Phase 2b Trial of Topsalysin in Prostate Cancer to Initiate Soon
finance.yahoo.com - May 19 at 10:05 AM
streetinsider.com logoSophiris Bio (SPHS) Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at AUA
www.streetinsider.com - May 16 at 7:54 PM
americanbankingnews.com logoSophiris Bio Inc (SPHS) Posts Earnings Results, Meets Estimates
www.americanbankingnews.com - May 16 at 10:54 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Snap, Home Depot, Pfizer, Akebia - Nasdaq
www.nasdaq.com - May 16 at 9:05 AM
finance.yahoo.com logoSophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights
finance.yahoo.com - May 15 at 7:09 PM
streetinsider.com logoSophiris Bio (SPHS) Presents Topsalysin Data from Phase 2a Proof ... - StreetInsider.com
www.streetinsider.com - May 15 at 9:12 AM
finance.yahoo.com logoSophiris Bio Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at 112th American Urological Association (AUA) Meeting
finance.yahoo.com - May 15 at 9:12 AM
americanbankingnews.com logoSophiris Bio Inc (SPHS) Short Interest Update
www.americanbankingnews.com - May 12 at 3:40 PM
americanbankingnews.com logo-$0.09 Earnings Per Share Expected for Sophiris Bio Inc (SPHS) This Quarter
www.americanbankingnews.com - May 9 at 12:28 PM
americanbankingnews.com logoSophiris Bio Inc (SPHS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 5 at 11:38 AM
americanbankingnews.com logoSophiris Bio (SPHS) Earning Positive Press Coverage, Study Finds
www.americanbankingnews.com - May 4 at 12:12 PM
americanbankingnews.com logoSophiris Bio (SPHS) Getting Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 25 at 11:44 AM
americanbankingnews.com logo Brokerages Expect Sophiris Bio Inc (SPHS) to Post -$0.09 Earnings Per Share
www.americanbankingnews.com - April 18 at 4:31 PM
americanbankingnews.com logoSophiris Bio (SPHS) Getting Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 18 at 3:45 PM
americanbankingnews.com logoSophiris Bio (SPHS) Earns Coverage Optimism Rating of 0.31
www.americanbankingnews.com - April 13 at 5:03 PM
americanbankingnews.com logoSophiris Bio Inc (SPHS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 10 at 11:44 AM
americanbankingnews.com logoSophiris Bio Inc (SPHS) Earns Overweight Rating from Piper Jaffray Companies
www.americanbankingnews.com - April 6 at 9:46 AM
americanbankingnews.com logoSophiris Bio Inc (SPHS) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 3 at 12:25 PM
americanbankingnews.com logoSophiris Bio Inc Forecasted to Post Q1 2017 Earnings of ($0.08) Per Share (SPHS)
www.americanbankingnews.com - March 31 at 10:32 AM
finance.yahoo.com logoSPHS: Phase 2b Trial of Topsalysin in Prostate Cancer Underway
finance.yahoo.com - March 30 at 12:13 AM

Social

Chart

Sophiris Bio (SPHS) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff